News & Updates
Filter by Specialty:
Adherence higher, discontinuation lower with ixekizumab vs secukinumab
Psoriasis patients treated with ixekizumab show better persistence and adherence over 24 months as well as a lower risk of discontinuation than those using secukinumab, reports a recent study that used real-world data.
Adherence higher, discontinuation lower with ixekizumab vs secukinumab
07 Mar 2022
Adding capecitabine to adjuvant chemo improves 15-year OS in early breast cancer
Adding capecitabine to adjuvant chemotherapy containing docetaxel, epirubicin and cyclophosphamide significantly improves 15-year overall survival (OS) in patients with early breast cancer, results of the phase III FinXX trial (Finland Capecitabine Trial) have shown.
Adding capecitabine to adjuvant chemo improves 15-year OS in early breast cancer
07 Mar 2022
AChEI use ups lung cancer risk in older, comorbid patients
Medication with acetylcholinesterase inhibitors (AChEI) increases the risk of lung cancer among older patients and those with several comorbidities, reports a recent study.
AChEI use ups lung cancer risk in older, comorbid patients
07 Mar 2022
Weight loss in T2D patients ups death risk, but lifestyle change can help
Mortality is heightened among type 2 diabetes (T2D) patients with substantial weight loss, but such risk can be attenuated by improving lifestyle quality, suggests a recent study.
